Join

Compare · CERS vs DASH

CERS vs DASH

Side-by-side comparison of Cerus Corporation (CERS) and DoorDash Inc. (DASH): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CERS and DASH operate in EDP Services (Technology), so they compete in similar markets.
  • DASH is the larger of the two at $35.57B, about 41.0x CERS ($866.5M).
  • Over the past year, CERS is up 47.8% and DASH is down 5.9% - CERS leads by 53.7 points.
  • DASH has been more active in the news (14 items in the past 4 weeks vs 4 for CERS).
  • DASH has more recent analyst coverage (25 ratings vs 3 for CERS).
PerformanceCERS+47.76%DASH-5.91%
2025-04-28+0.00%2026-04-24
MetricCERSDASH
Company
Cerus Corporation
DoorDash Inc.
Price
$1.98+4.49%
$176.78-0.14%
Market cap
$866.5M
$35.57B
1M return
+7.03%
+15.61%
1Y return
+47.76%
-5.91%
Industry
EDP Services
EDP Services
Exchange
NASDAQ
NYSE
IPO
1997
News (4w)
4
14
Recent ratings
3
25
CERS

Cerus Corporation

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.

DASH

DoorDash Inc.

DoorDash, Inc. operates a logistics platform that connects merchants, consumers, and dashers in the United States and internationally. It operates DoorDash marketplace, which provides an array of services that enable merchants to solve mission-critical challenges, such as customer acquisition, delivery, insights and analytics, merchandising, payment processing, and customer support; and offers DoorDash Drive, a white-label logistics service; DoorDash Storefront that enables merchants to offer consumers on-demand access to e-commerce. The company was formerly known as Palo Alto Delivery Inc. and changed its name to DoorDash, Inc. in 2015. DoorDash, Inc. was founded in 2013 and is headquartered in San Francisco, California.